bi 836880
mAbexperimentalMulti-specific
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 5, 2016 (NCT02674152)
Timeline
Indications
Mechanism of action
VPS51 inhibitor
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- bi 836880
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05249426 | Phase 1 | Feb 25, 2022 | Boehringer Ingelheim |
| NCT04499352 | Phase 2 | Sep 14, 2020 | Boehringer Ingelheim |
| NCT03861234 | Phase 1 | Jul 3, 2019 | Boehringer Ingelheim |
| NCT03972150 | Phase 1 | Jun 12, 2019 | Boehringer Ingelheim |
| NCT03468426 | Phase 1 | May 3, 2018 | Boehringer Ingelheim |
| NCT02689505 | Phase 1 | Apr 4, 2016 | Boehringer Ingelheim |
| NCT02674152 | Phase 1 | Jan 5, 2016 | Boehringer Ingelheim |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 7 | 7 | 2 | 2016 |
1 organizations
Page 1 / 1